{"nctId":"NCT02881957","briefTitle":"Hypovitaminosis D in Neurocritical Patients","startDateStruct":{"date":"2016-10-10","type":"ACTUAL"},"conditions":["Craniocerebral Trauma","Intracranial Aneurysm","Brain Neoplasms","Spinal Cord Injuries","Seizures","Meningitis","Stroke","Intracranial Hemorrhages","Critical Illness","Vitamin d Deficiency"],"count":274,"armGroups":[{"label":"Control","type":"PLACEBO_COMPARATOR","interventionNames":["Other: Placebo"]},{"label":"Vitamin D3","type":"EXPERIMENTAL","interventionNames":["Drug: Cholecalciferol"]}],"interventions":[{"name":"Cholecalciferol","otherNames":["vitamin D3"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patients \\>18 years of age\n* Patients admitted to the neurosurgery or neurology services\n* Patients admitted to a critical care unit\n* Informed consent\n* Expected to stay in the ICU for 48 hours or more\n* Vitamin D deficiency (\\<20ng/mL)\n\nExclusion Criteria:\n\n* Patients where a vitamin D level was not drawn within 48 hours of admission\n* Patients not randomized within 48 hours of admission\n* Readmitted patients to the critical care unit\n* Lack of informed consent\n* Prior supplementation with vitamin D\n* Severely impaired gastrointestinal function\n* Other trial participation\n* Pregnant or lactating women\n* Hypercalcemia (total calcium of \\>10.6 mg/dL or ionized serum calcium of \\>5.4 mg/dL\n* Tuberculosis history or clinical exam\n* Sarcoidosis history or clinical exam\n* Nephrolithiasis within the prior year\n* Patients not deemed suitable for study participation (ie, psychiatric disease, living remotely from the clinic, or prisoner status)\n* Pregnant or nursing women","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Intent-to-treat Hospital Length-of-stay","description":"Intent-to-treat hospital length-of-stay","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.9","spread":"15.6"},{"groupId":"OG001","value":"9.1","spread":"7.9"}]}]}]},{"type":"PRIMARY","title":"As-treated Hospital Length of Stay","description":"Two-sided t-test evaluated comparing length of stay in vitamin D3 vs. placebo treated patients utilizing patients after randomization, factoring excluded patients (e.g., as-treated) using a p\\<0.05 as significant.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.4","spread":"14.5"},{"groupId":"OG001","value":"9.1","spread":"7.9"}]}]}]},{"type":"SECONDARY","title":"Intent-to-treat ICU Length of Stay","description":"Two-sided t-test evaluated comparing length of stay within the ICU specifically in vitamin D3 vs. placebo treated patients utilizing patients after randomization (e.g., intent-to-treat) using a p\\<0.05 as significant.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.4","spread":"9.8"},{"groupId":"OG001","value":"5.4","spread":"6.4"}]}]}]},{"type":"SECONDARY","title":"As-treated ICU Length of Stay","description":"Two-sided t-test evaluated comparing length of stay within the ICU specifically in vitamin D3 vs. placebo treated patients utilizing patients after randomization but excluding patients who did not receive treatment (e.g., as-treated) using a p\\<0.05 as significant.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.8","spread":"7.5"},{"groupId":"OG001","value":"5.4","spread":"6.4"}]}]}]},{"type":"SECONDARY","title":"In-hospital Mortality","description":"In-hospital mortality","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null},{"groupId":"OG001","value":"13","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Study Drug Related Adverse Events","description":"The occurrence of patients who suffered mortality, adverse events or severe adverse events, related specifically to the study drug was monitored. Severe adverse events are defined using common terminology criteria for adverse events (CTCAE) grade 3 or higher specific to vitamin D from time of study drug administration to discharge.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Sepsis","description":"Diagnosis of sepsis","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Pneumonia","description":"Pneumonia diagnosis","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16","spread":null},{"groupId":"OG001","value":"14","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Urinary Tract Infection","description":"Urinary tract infection diagnosis","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null},{"groupId":"OG001","value":"6","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Deep Vein Thrombosis","description":"Deep vein thrombosis diagnosis","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":134},"commonTop":[]}}}